Skip to main navigation Skip to search Skip to main content

Binding of Janus kinase inhibitor tofacitinib with human serum albumin: multi-technique approach

Research output: Contribution to journal › Article › peer-review

Abstract

In this report, we have investigated the binding affinity of tofacitinib with human serum albumin (HSA) under simulated physiological conditions by using UV–visible spectroscopy, fluorescence quenching measurements, dynamic light scattering (DLS), differential scanning calorimetry (DSC) and molecular docking methods. The obtained results demonstrate that fluorescence intensity of HSA gets quenched by tofacitinib and quenching occurs in static manner. Binding parameters calculated from modified Stern–Volmer equation shows that the drug binds to HSA with a binding constant in the order of 105. Synchronous fluorescence data deciphered the change in the microenvironment of tryptophan residue in HSA. UV spectroscopy and DLS measurements deciphered complex formation and reduction in hydrodynamic radii of the protein, respectively. Further DSC results show that tofacitinib increases the thermo stability of HSA. Hydrogen bonding and hydrophobic interaction are the main binding forces between HSA and tofacitinib as revealed by docking results.

Original languageEnglish (US)
Pages (from-to)2037-2044
Number of pages8
JournalJournal of Biomolecular Structure and Dynamics
Volume34
Issue number9
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

  • binding
  • fluorescence quenching
  • molecular docking
  • serum albumin

Fingerprint

Dive into the research topics of 'Binding of Janus kinase inhibitor tofacitinib with human serum albumin: multi-technique approach'. Together they form a unique fingerprint.

Cite this